Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tofacitinib
Xeljanz
Not routinely available
SMC (SMC2463)
28/09/2022
Indication
For the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
5mg film-coated tablets
Comments
September 2022 - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.